{"id":933616,"date":"2026-02-03T08:09:03","date_gmt":"2026-02-03T13:09:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/"},"modified":"2026-02-03T08:09:03","modified_gmt":"2026-02-03T13:09:03","slug":"amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/","title":{"rendered":"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026"},"content":{"rendered":"
\n

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) — Amicus Therapeutics<\/u><\/a> (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold\u00ae<\/sup> (migalastat) in Fabry disease and POMBILITI\u00ae<\/sup> + OPFOLDA\u00ae<\/sup> (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the\u00a022nd Annual WORLD<\/u>Symposium<\/u><\/em>\u2122 2026<\/u><\/a>.<\/p>\n

\u201cAmicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year\u2019s WORLDSymposium<\/em>. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda,\u201d said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics, Inc. \u201cWe are immensely grateful to the patients, their families, and investigators whose partnership makes scientific research and advances possible.\u201d<\/p>\n

\n
\n Oral Presentations:<\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n
\n
\n Abstract Title<\/u>
\n <\/strong>\n <\/td>\n		\n
\n Disease <\/u>
\n <\/strong>\n <\/td>\n		\n
\n Presenter<\/u>
\n <\/strong>\n <\/td>\n		\n
\n Date and Time <\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
\n Real-world effectiveness of migalastat versus enzyme replacement therapy in previously treatment-na\u00efve patients with Fabry disease: analyses of matched populations from the global followME Pathfinders registry<\/em>\n <\/td>\nFabry<\/td>\nPeter Nordbeck, University of Wuerzburg, Wuerzburg, Germany<\/td>\nThursday, February 5, 8:30 a.m. PST<\/td>\n<\/tr>\n
\n 208-week outcomes of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers<\/em>\n <\/td>\nPompe<\/td>\nTahseen Mozaffar, University of California, Irvine, Irvine, CA, USA<\/td>\nFriday, February 6, 1:20 p.m. PST<\/td>\n<\/tr>\n<\/table>\n

\n
\n
\n
Poster Sessions<\/u>
\n <\/strong>\n <\/p>\n

\n Fabry Disease:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n Abstract Title<\/u>
\n <\/strong>\n <\/td>\n		\n
\n Presenter<\/u>
\n <\/strong>\n <\/td>\n		\n
\n Date and Time <\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
\n Exploring the lived experience of the Fabry community in Czechia <\/em>(Poster #378)<\/td>\nChristopher Wingrove, Amicus Therapeutics, Inc., Marlow, UK<\/td>\nTuesday, February 3, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n followME Fabry Pathfinders registry: cardiac and renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for 5 years <\/em>(Poster #266)<\/td>\nPeter Nordbeck, University of Wuerzburg, Wuerzburg, Germany<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Real-world effectiveness of migalastat versus enzyme replacement therapy in previously treatment-na\u00efve patients with Fabry disease: analyses of matched populations from the global followME Pathfinders registry <\/em>(Poster #267)<\/td>\nPeter Nordbeck, University of Wuerzburg, Wuerzburg, Germany<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Adjusted migalastat dose regimens in patients with Fabry disease and amenable GLA variants with severe renal impairment, or with end-stage renal disease and receiving hemodialysis\/hemodiafiltration (HD\/HDF): pharmacokinetic (PK) and safety results from a protocol-specified interim analysis of the RENEW study <\/em>(Poster #187)<\/td>\nFranklin K. Johnson, Amicus Therapeutics, Inc., Princeton, NJ, USA<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Trial in progress: an open-label study (AT1001-033; ASPIRE II) to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of migalastat in pediatric patients with Fabry disease <\/em>(Poster #384)<\/td>\nHaichen Yang, Amicus Therapeutics, Inc., Philadelphia, PA, USA<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n A structured methodology for evaluating patient-reported outcomes across a treatment program: a comparative application in migalastat <\/em>(Poster #127)<\/td>\nVera Gielen, Amicus Therapeutics, Inc., Marlow, UK<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Clinical characterization and healthcare usage in Fabry disease using Swedish national registers <\/em>(Poster #118)<\/td>\nEmma Flordal Thelander, Amicus Therapeutics, Inc., Stockholm, Sweden<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/p>\n<\/td>\n<\/tr>\n
\n followME Fabry Pathfinders real-world registry in Spain and Portugal: cardiac and renal outcomes with migalastat in patients with Fabry disease <\/em>(Poster #22)<\/td>\nOlga Azevedo, Hospital Senhora da Oliveira, Guimar\u00e3es, Portugal<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Matching-adjusted indirect comparisons (MAICs) and network meta-analyses (NMAs) of the oral small-molecule chaperone migalastat versus intravenous enzyme replacement therapies (ERTs) for clinical measures in Fabry disease <\/em>(Poster #128)<\/td>\nVera Gielen, Amicus Therapeutics, Inc., Marlow, UK<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Long-term safety and effectiveness of migalastat in patients with Fabry disease: results from the Korean post-marketing surveillance <\/em>(Poster #168)<\/td>\nGeu-Ru Hong, Severance Cardiovascular Hospital, Seoul, Korea<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n<\/table>\n

\n
\n
Pompe Disease:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n Abstract Title<\/u>
\n <\/strong>\n <\/td>\n		\n
\n Presenter<\/u>
\n <\/strong>\n <\/td>\n		\n
\n Date and Time <\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
\n 208-week outcomes of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: pulmonary function <\/em>(Poster #205)<\/td>\nPriya S. Kishnani, Duke University, Durham, NC, USA<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n 208-week outcomes of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: Muscle function and biomarkers <\/em>(Poster #257)<\/td>\nTahseen Mozaffar, University of California, Irvine, Irvine, CA, USA<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n 90-month muscle function and biomarker outcomes with cipaglucosidase alfa plus miglustat (cipa+mig) in adults with Pompe disease in ATB200-02, an open-label phase I\/II study <\/em>(Poster #313)<\/td>\nBenedikt Schoser, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n 90-month pulmonary function outcomes with cipaglucosidase alfa plus miglustat (cipa+mig) in adults with Pompe disease in ATB200-02, an open-label phase I\/II study <\/em>(Poster #206)<\/td>\nPriya S. Kishnani, Duke University, Durham, NC, USA<\/p>\n<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n 90-month physician and patient-reported outcomes with cipaglucosidase alfa plus miglustat (cipa+mig) in adults with Pompe disease in ATB200-02, an open-label phase I\/II study <\/em>(Poster #299)<\/td>\nMark Roberts, Salford Royal NHS Foundation Trust, Salford, UK<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n From frustration to function: reimagining registry value with individual monitoring dashboards to visualize disease progression in Pompe disease <\/em>(Poster #247)<\/td>\nPaul McIntosh, University of Pennsylvania, Philadelphia, PA, USA<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/p>\n<\/td>\n<\/tr>\n
\n ROSSELLA: an ongoing open-label, multicenter, global trial to study next-generation treatment of infantile-onset Pompe disease combining enzyme replacement with a stabilizing iminosugar <\/em>(Poster #244)<\/td>\nThorsten Marquardt, University of M\u00fcnster, M\u00fcnster, Germany<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Impact of mobility-aid use on late-onset Pompe disease (LOPD) patient experience: insights from patient interviews <\/em>(Poster #178)<\/td>\nDerralynn Hughes, Royal Free London NHS Foundation Trust, University College London, London, UK<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n
\n Delayed diagnosis and missed opportunities: results from an analysis of the diagnostic journey for LOPD in the UK <\/em>(Poster #82)<\/td>\nPatrick Deegan, Cambridge University Hospitals NHS Foundation Trust (CUH), Cambridge, UK<\/td>\nThursday, February 5, 3:30 \u2013 5:30 p.m. PST<\/td>\n<\/tr>\n<\/table>\n

\n
\n
\n
About Galafold<\/u>
\n <\/strong>
\n
Galafold\u00ae<\/sup>\u00a0(migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable\u00a0galactosidase alpha gene\u00a0(GLA)<\/em>\u00a0variants. In these patients, Galafold works by stabilizing the body\u2019s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of people living with Fabry disease may have amenable\u00a0GLA<\/em>\u00a0variants, though amenability rates within this range vary by geography. Galafold is approved in more than 40 countries around the world, including the U.S., EU, U.K., and Japan.<\/p>\n

\n U.S. INDICATIONS AND USAGE<\/strong>
\n
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA<\/em>) variant based on\u00a0in\u00a0vitro<\/em>\u00a0assay data.<\/p>\n

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.<\/p>\n

\n U.S. IMPORTANT SAFETY INFORMATION<\/strong>\n <\/p>\n

\n ADVERSE REACTIONS:\u00a0<\/strong>The most common adverse reactions reported with Galafold (\u226510%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.\u00a0<\/p>\n

\n USE IN SPECIFIC POPULATIONS:\u00a0<\/strong>There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition. Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. The safety and effectiveness of Galafold have not been established in pediatric patients. To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at\u00a01-800-FDA-1088 or\u00a0www.fda.gov\/medwatch<\/a>.\u00a0For additional information about Galafold, please see the <\/strong>full U.S. Prescribing Information<\/strong><\/a>.<\/p>\n

\n
\n About Pombiliti + Opfolda<\/u>
\n <\/strong>
\n
Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that\u2019s designed to reduce loss of enzyme activity in the blood.<\/p>\n

\n U.S. INDICATIONS<\/strong>\u00a0AND<\/strong>\u00a0USAGE<\/strong>
POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing \u226540 kg and who are not improving on their current enzyme replacement therapy (ERT).<\/p>\n

\n SAFETY INFORMATION<\/strong>\n <\/p>\n

\n HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION:<\/strong>\u00a0POMBILITI in combination with Opfolda is contraindicated in pregnancy.\u00a0EMBRYO-FETAL TOXICITY:<\/strong>\u00a0May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose.\u00a0Adverse Reactions:<\/strong>\u00a0Most common adverse reactions \u2265 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia.\u00a0Please see <\/strong>full PRESCRIBING INFORMATION<\/strong><\/a>,<\/strong> including BOXED WARNING, for POMBILITI (cipaglucosidase alfa-atga<\/strong>)\u00a0<\/strong>and <\/strong>full PRESCRIBING INFORMATION<\/strong><\/a> for OPFOLDA (miglustat).<\/strong><\/p>\n

\n
\n About WORLD<\/u>
\n <\/strong>
\n
\n
\n Symposium<\/u>
\n <\/em>
\n <\/strong>
\n
WORLDSymposium<\/em>\u00a0is designed for basic, translational and clinical researchers, patient advocacy groups, clinicians, and all others who are interested in learning more about the latest discoveries related to lysosomal diseases and the clinical investigation of these advances. Each year, WORLDSymposium<\/em> presents the latest information from basic science, translational research, and clinical trials for lysosomal diseases. For more information, please visit\u00a0<\/strong>www.worldsymposia.org<\/a>.<\/p>\n

\n
\n About Amicus Therapeutics<\/u>
\n <\/strong>
\n
Amicus Therapeutics (Nasdaq: FOLD) is a leading, global biotechnology company with a clear and compelling mission: to develop and deliver transformative medicines for people living with rare diseases. With extraordinary patient focus, Amicus strives to redefine expectations in rare disease. For more information please visit the company\u2019s website at\u00a0www.amicusrx.com<\/a>, and follow on LinkedIn<\/a>.<\/p>\n

CONTACT:<\/p>\n

\n Investors:<\/strong>
\n
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809<\/p>\n

\n Media:<\/strong>
\n
Amicus Therapeutics
Brendan McEvoy
Executive Director, External Communications
bmcevoy@amicusrx.com
(609) 662-5005<\/p>\n

CRPA-PF-US-26-00001-1<\/p>\n

FOLD-G<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold\u00ae (migalastat) in Fabry disease and POMBILITI\u00ae + OPFOLDA\u00ae (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the\u00a022nd Annual WORLDSymposium\u2122 2026. \u201cAmicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year\u2019s WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda,\u201d said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics, Inc. \u201cWe are immensely grateful to the patients, their families, and … <\/p>\n

Continue reading “Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933616","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAmicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold\u00ae (migalastat) in Fabry disease and POMBILITI\u00ae + OPFOLDA\u00ae (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the\u00a022nd Annual WORLDSymposium\u2122 2026. \u201cAmicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year\u2019s WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda,\u201d said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics, Inc. \u201cWe are immensely grateful to the patients, their families, and … Continue reading "Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T13:09:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026\",\"datePublished\":\"2026-02-03T13:09:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/\"},\"wordCount\":1703,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/\",\"name\":\"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=\",\"datePublished\":\"2026-02-03T13:09:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/","og_locale":"en_US","og_type":"article","og_title":"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026 - Market Newsdesk","og_description":"PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold\u00ae (migalastat) in Fabry disease and POMBILITI\u00ae + OPFOLDA\u00ae (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the\u00a022nd Annual WORLDSymposium\u2122 2026. \u201cAmicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year\u2019s WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda,\u201d said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics, Inc. \u201cWe are immensely grateful to the patients, their families, and … Continue reading \"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-03T13:09:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026","datePublished":"2026-02-03T13:09:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/"},"wordCount":1703,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/","name":"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=","datePublished":"2026-02-03T13:09:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI2OCM3NDA0Nzg1IzIwMDU2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-presents-new-long-term-data-for-both-galafold-migalastat-and-pombiliti-cipaglucosidase-alfa-atga-opfolda-miglustat-at-the-22nd-annual-worldsymposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amicus Therapeutics Presents New Long-term Data for both Galafold\u00ae (migalastat) and POMBILITI\u00ae (cipaglucosidase alfa-atga) + OPFOLDA\u00ae (miglustat) at the 22nd Annual WORLDSymposium\u2122 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933616"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}